Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 6 institutions in 2 countries.
Danielle H Oh *Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.ORCID 0000-0001-9804-1449
Xiao Ma *Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville VIC 3052, Australia.ORCID 0000-0002-9842-9045
Simon J HoggCancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.
Jackson HeBlood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.ORCID 0000-0002-3154-5121
Conor KearneyOlivia Newton-John Cancer Research Institute, Heidelberg VIC 3084, Australia.
Daniella BrasacchioBlood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.ORCID 0000-0001-5956-9611
Olivia SusantoBlood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.
Belinda MaherBlood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.ORCID 0000-0002-8900-6876
Ian G JenningsMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville VIC 3052, Australia.
Andrea NewboldCancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.
Peter FraserCancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.ORCID 0009-0001-6955-4955
Emily GruberCancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.
Lev M KatsCancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.ORCID 0000-0001-8742-8138
Gareth P GregoryBlood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.
Ricky W Johnstone *Cancer Biology Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne VIC 3000, Australia.
Philip E Thompson *Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville VIC 3052, Australia.ORCID 0000-0002-5910-7625
Jake Shortt *Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne VIC 3168, Australia.ORCID 0000-0003-3185-6488
The University of Melbourne · AUMonash Health · AUPeter MacCallum Cancer Centre · AUMonash University · AUHarvard University · USLa Trobe University · AU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Targeted inhibitors of bromodomain and extraterminal (BET)-bromodomains and phosphatidylinositol-3-kinase (PI3K) signaling demonstrate potent but self-limited antilymphoma activity as single agents in the context of cellular Myelocytomatosis (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma. · full record | OpenQuestion